Abstract:
A lightweight, impact-resistant gas turbine blade, such as an aircraft engine fan blade, includes a metallic airfoil portion with at least one surface recess containing a void volume having adjacent first and second regions. Filler material is placed in and bonded to the surface recess and generally completely fills the void volume. The filler material in the first region has a higher average modulus of elasticity than that of the filler material in the second region.
Abstract:
A system for controlling viewing of multimedia is provided. The system includes an image capturing module captures images or videos of a user while viewing the multimedia. A mouth gesture identification module extracts facial features from the images captured of the user; identifies mouth gestures of the user based on the facial features extracted. A training module analyses the mouth gestures identified to determine parameters; builds a personalised support model for the user based on the parameters determined. A prediction module receives real-time images captured, wherein the real-time images are captured while viewing the multimedia; extract real-time facial features from the real-time images captured; identifies real-time mouth gestures of the user based on the real-time facial features extracted; analyze the real-time mouth gestures identified to determine real-time parameters; compare the real-time parameters determined with the personalized support model built for the user, and control outputs based on compared data.
Abstract:
In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.
Abstract:
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Abstract:
In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF 11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
Abstract:
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.
Abstract:
A strengthened glass sheet or article having an edge profile that provides improved edge strength, particularly when the strengthened glass sheet is subjected to a four point bend test, and a method of making a glass sheet having such an edge. The edge is formed by cutting or other separation methods and then ground to a predetermined profile such as a pencil or bullet profile, a bull nose profile, or the like. In some embodiments, the edge is polished and/or etched following grinding to reduce flaw size.
Abstract:
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Abstract:
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
Abstract:
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.